{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:02:27Z","timestamp":1765958547836,"version":"3.48.0"},"reference-count":57,"publisher":"Begell House","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Crit Rev Eukaryot Gene Expr"],"published-print":{"date-parts":[[2025]]},"abstract":"<p>&lt;b&gt;Background:&lt;\/b&gt; This study aims to provide a comprehensive overview of the current research status of RTX in pediatric renal disease treatment through bibliometric and visualization analyses, thereby enabling researchers to swiftly identify research hotspots and anticipate future trends.\n\n&lt;b&gt;Methods:&lt;\/b&gt; The Web of Science Core Collection served as the primary database for literature retrieval. We selected English-language papers and reviews relevant to our research topic and extracted pertinent information. The data were subsequently subjected to a multifaceted and multilevel bibliometric analysis utilizing VOSviewer, CiteSpace, and Bibliometrix.\n\n&lt;b&gt;Results: &lt;\/b&gt;Our search yielded and screened a total of 525 articles. The analysis revealed a consistent increase in publication outputs and citation frequency in this field from 2003 to 2024, with contributions from 2,797 researchers across 54 countries and regions, and 966 academic institutions. The United States led in article output, with 105 publications, and Assistance Publique Hopitaux Paris in France emerged as a prominent research institution, with 49 publications. Within the research domain, approximately 52 core authors were identified, with one author emerging as the most influential and prolific, having published 31 papers and accumulated 1,258 citations. &lt;i&gt;Pediatric Nephrology&lt;\/i&gt; was the most frequently publishing journal in this field, with 127 papers, nearly a quarter of the total. A paper in &lt;i&gt;The Lancet,&lt;\/i&gt; titled \"Pediatric nephrology,\" gained significant attention in the field. Additionally, a publication in &lt;i&gt;The Lancet &lt;\/i&gt;entitled \"Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: A multidisciplinary approach\" received notable recognition. The most frequently cited article over the past two decades was \"Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: A multicenter, double-blind, randomized placebo-controlled trial.\" Notably, the most frequently cited key words in recent years included \"nephrotic syndrome,\" \"focal segmental glomerulosclerosis,\" and terms related to \"mycoplasma,\" as well as \"mycophenloate-mofetil,\" \"cyclosporine,\" \"multicenter,\" and \"double-blind,\" with nephrotic syndrome being the most discussed disease.\n\n&lt;b&gt;Conclusions: &lt;\/b&gt;This study reveals a consistent increase in publication output and citation frequency in this field from 2003 to 2024, highlighting the significant impact of RTX in the global arena of pediatric renal disease treatment. These findings not only offer researchers a rapid grasp of current research hotspots but also provide a basis for predicting future research trends, further supporting the potential and significance of RTX in the treatment of pediatric renal diseases.<\/p>","DOI":"10.1615\/critreveukaryotgeneexpr.2025061540","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T16:44:21Z","timestamp":1762361061000},"page":"61-79","source":"Crossref","is-referenced-by-count":0,"title":["Use of Rituximab in Pediatric Nephrology: A Bibliometric and Visualization Analysis from 2003 to 2024"],"prefix":"10.1615","volume":"35","author":[{"given":"Huijian","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengyou","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"613","reference":[{"key":"2","doi-asserted-by":"crossref","unstructured":"Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, Adebayo OM, Afarideh M, Agarwal SK, Agudelo-Botero M, Ahmadian E. Global, regional, and national burden of chronic kidney disease, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709-33.","DOI":"10.1016\/S0140-6736(20)30045-3"},{"key":"3","unstructured":"Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco AL, De Jong PE, Griffith KE, Hemmelgarn BR, Iseki K, Lamb EJ, Levey AS. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1-50."},{"key":"4","doi-asserted-by":"crossref","unstructured":"Tang Y, Jiang J, Zhao Y, Du D. Aging and chronic kidney disease: Epidemiology, therapy, management and the role of immunity. Clin Kidney J. 2024;17(9):sfae235.","DOI":"10.1093\/ckj\/sfae235"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Chesnaye NC, Carrero JJ, Hecking M, Jager KJ. Differences in the epidemiology, management and outcomes of kidney disease in men and women. Nat Rev Nephrol. 2024;20(1):7-20.","DOI":"10.1038\/s41581-023-00784-z"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Johansen KL, Gilbertson DT, Li S, Li S, Liu J, Roetker NS, Ku E, Schulman IH, Greer RC, Chan K, Abbott KC, Butler CR, O'Hare AM, Powe NR, Reddy YNV, Snyder J, St Peter W, Taylor JS, Weinhandl ED, Wetmore JB. US Renal Data System 2023 annual data report: Epidemiology of kidney disease in the United States. Am J Kidney Dis. 2024;83(4 Suppl 1):A8-A13.","DOI":"10.1053\/j.ajkd.2024.01.001"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Cirillo L, De Chiara L, Innocenti S, Errichiello C, Romagnani P, Becherucci F. Chronic kidney disease in children: An update. Clin Kidney J. 2023;16(10):1600-11.","DOI":"10.1093\/ckj\/sfad097"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Iijima K, Sako M, Nozu K. Rituximab for nephrotic syndrome in children. Clin Exp Nephrol. 2017;21(2):193-202.","DOI":"10.1007\/s10157-016-1313-5"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Techa-Angkoon P, Siritho S, Tisavipat N, Suansanae T. Current evidence of rituximab in the treatment of multiple sclerosis. Mult Scler Relat Disord. 2023;75:104729.","DOI":"10.1016\/j.msard.2023.104729"},{"key":"10","doi-asserted-by":"crossref","unstructured":"McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389(10086):2328-37.","DOI":"10.1016\/S0140-6736(17)31472-1"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Furer V, Eviatar T, Zisman D, Peleg H, Paran D, Levartovsky D, Zisapel M, Elalouf O, Kaufman I, Meidan R, Broyde A, Polachek A, Wollman J, Litinsky I, Meridor K, Nochomovitz H, Silberman A, Rosenberg D, Feld J, Haddad A, Gazzit T, Elias M, Higazi N, Kharouf F, Shefer G, Sharon O, Pel S, Nevo S, Elkayam O. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: A multicentre study. Ann Rheum Dis. 2021;80(10):1330-8.","DOI":"10.1136\/annrheumdis-2021-220647"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Kohle F, Wunderlich G, Fink GR, Schroeter M, Lehmann HC, Schneider C. Rituximab in non-systemic vasculitic neuropathy: A single-center experience. J Neurol. 2024;271(7):4406-11.","DOI":"10.1007\/s00415-024-12378-1"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Furuta S, Nakagomi D, Kobayashi Y, Hiraguri M, Sugiyama T, Amano K, Umibe T, Kono H, Kurasawa K, Kita Y, Matsumura R, Kaneko Y, Ninagawa K, Hiromura K, Kagami SI, Inaba Y, Hanaoka H, Ikeda K, Nakajima H; LoVAS Collaborators. Effect of reduced-dose vs highdose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: A randomized clinical trial. JAMA. 2021;325(21):2178-87.","DOI":"10.1001\/jama.2021.6615"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Shipa M, Embleton-Thirsk A, Parvaz M, Santos LR, Muller P, Chowdhury K, Isenberg DA, Dor\u00e9 CJ, Gordon C, Ehrenstein MR; BEAT-LUPUS Investigators. Effectiveness of belimumab after rituximab in systemic lupus erythematosus: A randomized controlled trial. Ann Intern Med. 2021;174(12):1647-57.","DOI":"10.7326\/M21-2078"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Konstantinov K, Dolladille C, Gillet B, Alexandre J, Aouba A, Deshayes S, Repesse Y. Drug-associated acquired hemophilia A: An analysis based on 185 cases from the WHO pharmacovigilance database. Haemophilia. 2023;29(1):186-92.","DOI":"10.1111\/hae.14692"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Choi N, Min J, Kim JH, Kang HG, Ahn YH. Efficacy and safety of long-term repeated use of rituximab in pediatric patients with nephrotic syndrome. Pediatr Nephrol. 2024;39(3):771-80.","DOI":"10.1007\/s00467-023-06124-4"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Chan EY, Wong SW, Lai FF, Ho TW, Tong PC, Lai WM, Ma AL, Yap DY. Long-term outcomes with rituximab as add-on therapy in severe childhood-onset lupus nephritis. Pediatr Nephrol. 2023;38(12):4001-11.","DOI":"10.1007\/s00467-023-06025-6"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Chan EY, Sinha A, Yu ELM, Akhtar N, Angeletti A, Bagga A, Banerjee S, Boyer O, Chan CY, Francis A, Ghiggeri GM, Hamada R, Hari P, Hooman N, Hopf LS, I MI, Ijaz I, Ivanov DD, Kalra S, Kang HG, Lucchetti L, Lugani F, Ma AL, Morello W, Camargo Muniz MD, Pradhan SK, Prikhodina L, Raafat RH, Sinha R, Teo S, Tomari K, Vivarelli M, Webb H, Yap HK, Yap DY, Tullus K. An international, multi-center study evaluated rituximab therapy in childhood steroid-resistant nephrotic syndrome. Kidney Int. 2024;106(6):1146-57.","DOI":"10.1016\/j.kint.2024.09.011"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Hicks D, Wouters P, Waltman L, de Rijcke S, Rafols I. Bibliometrics: The Leiden Manifesto for research metrics. Nature. 2015;520(7548):429-31.","DOI":"10.1038\/520429a"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Wan Y, Shen J, Ouyang J, Dong P, Hong Y, Liang L, Liu J. Bibliometric and visual analysis of neutrophil extracellular traps from 2004 to 2022. Front Immunol. 2022;13:1025861. doi: 10.3389\/fimmu.2022.1025861. Erratum in: Front Immunol. 2022 Dec 08;13:1098082.","DOI":"10.3389\/fimmu.2022.1025861"},{"key":"21","unstructured":"Osinska V, Klimas R. Mapping science: Tools for bibliometric and altmetric studies. Gdansk, Poland: Gdansk University Press; 2021."},{"key":"22","doi-asserted-by":"crossref","unstructured":"Chen C. CiteSpace II: Detecting and visualizing emerging trends and transient patterns in scientific literature. J Am Soc Inf Sci Technol. 2006;57(3):359-77.","DOI":"10.1002\/asi.20317"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Liu Z, Yin Y, Liu W, Dunford M. Visualizing the intellectual structure and evolution of innovation systems research: A bibliometric analysis. Scientometrics. 2015;103(1):135-58.","DOI":"10.1007\/s11192-014-1517-y"},{"key":"24","doi-asserted-by":"crossref","unstructured":"van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523-38.","DOI":"10.1007\/s11192-009-0146-3"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Aria M, Cuccurullo C. Bibliometrix: An R-tool for comprehensive science mapping analysis. J Informetr. 2017;11(4):959-75.","DOI":"10.1016\/j.joi.2017.08.007"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Brandes U. A faster algorithm for betweenness centrality. J Mathemat Soc. 2001;25(2):163-77.","DOI":"10.1080\/0022250X.2001.9990249"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Newman ME. Detecting community structure in networks. Eur Phys J B. 2004;38(2):321-30.","DOI":"10.1140\/epjb\/e2004-00124-y"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, Saito M, Yoneko M, Iijima K. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol. 2009;24(7):1321-8.","DOI":"10.1007\/s00467-009-1191-0"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Vivarelli M, Moscaritolo E, Tsalkidis A, Massella L, Emma F. Time for initial response to steroids is a major prognostic factor in idiopathic nephrotic syndrome. J Pediatr. 2010;156(6):965-71.","DOI":"10.1016\/j.jpeds.2009.12.020"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Ito S, Kamei K, Ogura M, Sato M, Fujimaru T, Ishikawa T, Udagawa T, Iijima K. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2011;26(10):1823-8.","DOI":"10.1007\/s00467-011-1886-x"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Ghiggeri GM, Musante L, Candiano G, Bruschi M, Santucci L, Barbano G, Trivelli A, Rivabella L, Gusmano R, Perfumo F. Protracted remission of proteinuria after combined therapy with plasmapheresis and anti-CD20 antibodies\/cyclophosphamide in a child with oligoclonal IgM and glomerulosclerosis. Pediatr Nephrol. 2007;22(11):1953-6.","DOI":"10.1007\/s00467-007-0550-y"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: A multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2014;384(9950):1273-81.","DOI":"10.1016\/S0140-6736(14)60541-9"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Ishikura K, Ikeda M, Hamasaki Y, Hataya H, Nishimura G, Hiramoto R, Honda M. Nephrotic state as a risk factor for developing posterior reversible encephalopathy syndrome in paediatric patients with nephrotic syndrome. Nephrol Dial Transplant. 2008;23(8):2531-6.","DOI":"10.1093\/ndt\/gfn013"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Sako M, Nakanishi K, Obana M, Yata N, Hoshii S, Takahashi S, Wada N, Takahashi Y, Kaku Y, Satomura K, Ikeda M, Honda M, Iijima K, Yoshikawa N. Analysis of NPHS1, NPHS2, ACTN4, and WT1 in Japanese patients with congenital nephrotic syndrome. Kidney Int. 2005;67(4):1248-55.","DOI":"10.1111\/j.1523-1755.2005.00202.x"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Emma F, Sesto A, Rizzoni G. Long-term linear growth of children with severe steroid-responsive nephrotic syndrome. Pediatr Nephrol. 2003;18(8):783-8.","DOI":"10.1007\/s00467-003-1176-3"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Colucci M, Carsetti R, Cascioli S, Casiraghi F, Perna A, Rav\u00e0 L, Ruggiero B, Emma F, Vivarelli M. B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome. J Am Soc Nephrol. 2016;27(6):1811-22.","DOI":"10.1681\/ASN.2015050523"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Ogura M, Kikuchi E, Kaito H, Kamei K, Matsuoka K, Tanaka H, Kuroda T, Sekine T, Ito S. ABO-incompatible renal transplantation in Epstein syndrome. Clin Transplant. 2010;24(Suppl 22):31-4.","DOI":"10.1111\/j.1399-0012.2010.01274.x"},{"key":"38","unstructured":"Lotka AJ. The frequency distribution of scientific productivity. Journal of the Washington academy of sciences. 1926;16(12):317-23."},{"key":"39","doi-asserted-by":"crossref","unstructured":"Hirsch JE. An index to quantify an individual's scientific research output. Proceedings of the National Academy of Sciences. 2005;102(46):16569-72.","DOI":"10.1073\/pnas.0507655102"},{"key":"40","doi-asserted-by":"crossref","unstructured":"Koh A, Lewis-Lloyd CA, Wong T, Lobo DN. Correlation between Altmetric Attention Scores and citation scores across the high impact-factor journals each in Medicine, Surgery, and Anaesthesia. Br J Anaesth. 2025;134(3):703-12.","DOI":"10.1016\/j.bja.2024.09.034"},{"key":"41","doi-asserted-by":"crossref","unstructured":"Yang L, Han L, Liu N. A new approach to journal co-citation matrix construction based on the number of co-cited articles in journals. Scientometrics. 2019;120(2):507-17.","DOI":"10.1007\/s11192-019-03141-9"},{"key":"42","unstructured":"Bradford SC. Sources of information on specific subjects. Engineering. 1934;137(3550):85-6."},{"key":"43","doi-asserted-by":"crossref","unstructured":"Chen C, Leydesdorff L. Patterns of connections and movements in dual\u00e2\u0080\u0090map overlays: A new method of publication portfolio analysis. Journal of the association for information science and technology. 2014;65(2):334-51.","DOI":"10.1002\/asi.22968"},{"key":"44","doi-asserted-by":"crossref","unstructured":"Ravani P, Rossi R, Bonanni A, Quinn RR, Sica F, Bodria M, Pasini A, Montini G, Edefonti A, Belingheri M, De Giovanni D, Barbano G, Degl'Innocenti L, Scolari F, Murer L, Reiser J, Fornoni A, Ghiggeri GM. Rituximab in children with steroid-dependent nephrotic syndrome: A multicenter, open-label, noninferiority, randomized controlled trial. J Am Soc Nephrol. 2015;26(9):2259-66.","DOI":"10.1681\/ASN.2014080799"},{"key":"45","doi-asserted-by":"crossref","unstructured":"Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, Groothoff J, Llanas B, Niaudet P, Nivet H, Raynaud N, Taque S, Ronco P, Bouissou F. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: A multicentric series of 22 cases. Pediatr Nephrol. 2008;23(8):1269-79.","DOI":"10.1007\/s00467-008-0814-1"},{"key":"46","doi-asserted-by":"crossref","unstructured":"Ruggenenti P, Ruggiero B, Cravedi P, Vivarelli M, Massella L, Maras\u00e0 M, Chianca A, Rubis N, Ene-Iordache B, Rudnicki M, Pollastro RM, Capasso G, Pisani A, Pennesi M, Emma F, Remuzzi G. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol. 2014;25(4):850-63.","DOI":"10.1681\/ASN.2013030251"},{"key":"47","doi-asserted-by":"crossref","unstructured":"Chan EY, Webb H, Yu E, Ghiggeri GM, Kemper MJ, Ma AL, Yamamura T, Sinha A, Bagga A, Hogan J, Dossier C, Vivarelli M, Liu ID, Kamei K, Ishikura K, Saini P, Tullus K. Both the rituximab dose and maintenance immunosuppression in steroid-dependent\/frequently-relapsing nephrotic syndrome have important effects on outcomes. Kidney Int. 2020;97(2):393-401.","DOI":"10.1016\/j.kint.2019.09.033"},{"key":"48","doi-asserted-by":"crossref","unstructured":"Kemper MJ, Gellermann J, Habbig S, Krmar RT, Dittrich K, Jungraithmayr T, Pape L, Patzer L, Billing H, Weber L, Pohl M, Rosenthal K, Rosahl A, Mueller-Wiefel DE, D\u00f6tsch J. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant. 2012;27(5):1910-5.","DOI":"10.1093\/ndt\/gfr548"},{"key":"49","doi-asserted-by":"crossref","unstructured":"Gulati A, Sinha A, Jordan SC, Hari P, Dinda AK, Sharma S, Srivastava RN, Moudgil A, Bagga A. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: Multicentric report. Clin J Am Soc Nephrol. 2010;5(12):2207-12.","DOI":"10.2215\/CJN.03470410"},{"key":"50","doi-asserted-by":"crossref","unstructured":"Basu B, Sander A, Roy B, Preussler S, Barua S, Mahapatra TKS, Schaefer F. Efficacy of rituximab vs. tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: A randomized clinical trial. JAMA Pediatr. 2018;172(8):757-64.","DOI":"10.1001\/jamapediatrics.2018.1323"},{"key":"51","doi-asserted-by":"crossref","unstructured":"Lee JM, Kronbichler A, Shin JI, Oh J. Current understandings in treating children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2021;36(4):747-61.","DOI":"10.1007\/s00467-020-04476-9"},{"key":"52","doi-asserted-by":"crossref","unstructured":"Jellouli M, Charfi R, Maalej B, Mahfoud A, Trabelsi S, Gargah T. Rituximab in the management of pediatric steroid-resistant nephrotic syndrome: A systematic review. J Pediatr. 2018;197:191-197.e1.","DOI":"10.1016\/j.jpeds.2018.01.008"},{"key":"53","doi-asserted-by":"crossref","unstructured":"Yokota S, Kamei K, Fujinaga S, Hamada R, Inaba A, Nishi K, Sato M, Ogura M, Sakuraya K, Ito S. Efficacy of rituximab and risk factors for poor prognosis in patients with childhood-onset steroid-resistant nephrotic syndrome: A multicenter study. Pediatr Nephrol. 2024;39(10):2979-88.","DOI":"10.1007\/s00467-024-06422-5"},{"key":"54","doi-asserted-by":"crossref","unstructured":"Tsuzuki Y, Shiomi R, Ashitani K, Miyaguchi K, Osaki A, Ohgo H, Kim R, Sasaki A, Yamada T, Miyakawa Y, Nakamoto H. Rituximab-induced ileocolitis in a patient with gastric MALToma: A case report and literature review. Internal Medicine. 2021;60(5):731-8.","DOI":"10.2169\/internalmedicine.5119-20"},{"key":"55","doi-asserted-by":"crossref","unstructured":"Alsubaie MA, Bahkali AB, Alhudaifi SA, Osaylan MT, Alghamdi AM, Nashawi M, Althubaiti FA. The indications and safety of rituximab for the treatment of pediatric autoimmune diseases: A single-center retrospective study. Transl Pediatr. 2024;13(10):1696-702.","DOI":"10.21037\/tp-24-233"},{"key":"56","doi-asserted-by":"crossref","unstructured":"Chen Y, Shen Q, Xiong Y, Dong M, Xu H, Li Z. Using real-world data to inform dosing strategies of rituximab for pediatric patients with frequent-relapsing or steroid-dependent nephrotic syndrome: A prospective pharmacokinetic-pharmacodynamic study. Front Pharmacol. 2024;14:1319744.","DOI":"10.3389\/fphar.2023.1319744"},{"key":"57","doi-asserted-by":"crossref","unstructured":"\u00dcnal A, Levento\u011flu E, Bakkaloglu SA. Rituximab use in paediatric nephrology practice in T\u00fcrkiye: TRTX. Nephrology. 2024;29(5):259-67.","DOI":"10.1111\/nep.14265"},{"key":"58","doi-asserted-by":"crossref","unstructured":"Li F, Hu C, Luo X. Research hotspots and frontiers of machine learning in renal medicine: A bibliometric and visual analysis from 2013 to 2024. Int Urol Nephrol. 2025;57(3):907-28.","DOI":"10.1007\/s11255-024-04259-3"}],"container-title":["Critical Reviews in Eukaryotic Gene Expression"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dl.begellhouse.com\/download\/article\/222a2eae09c523b1\/CRE-61540.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T07:58:25Z","timestamp":1765958305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dl.begellhouse.com\/journals\/6dbf508d3b17c437,22b25596365788b3,222a2eae09c523b1.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":57,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1615\/critreveukaryotgeneexpr.2025061540","relation":{},"ISSN":["1045-4403"],"issn-type":[{"type":"print","value":"1045-4403"}],"subject":[],"published":{"date-parts":[[2025]]}}}